Literature DB >> 18294632

Chronic administration of morphine is associated with a decrease in surface AMPA GluR1 receptor subunit in dopamine D1 receptor expressing neurons in the shell and non-D1 receptor expressing neurons in the core of the rat nucleus accumbens.

Michael J Glass1, Diane A Lane, Eric E O Colago, June Chan, Stefan D Schlussman, Yan Zhou, Mary Jeanne Kreek, Virginia M Pickel.   

Abstract

The nucleus accumbens (Acb) is an extensively studied neuroanatomical substrate of opiate reward and the neural plasticity associated with chronic opioid use. The cellular mechanisms mediating opioid-dependent plasticity are uncertain, however AMPA-type glutamate receptor trafficking in dopamine D1 dopamine receptor (D1R) expressing neurons may be a potential cellular pathway for these adaptations, although there is no evidence for this possibility. Immunogold electron microscopy was used to quantify the surface expression of the AMPA GluR1 subunit in dendritic profiles of neurons in the Acb in response to intermittent 14-day non-contingent injections of escalating doses of morphine, a model that parallels opioid self-administration. To determine if changes in GluR1 trafficking occurred in neurons potentially sensitive to dopamine-induced D1R activation, immunoperoxidase labeling of D1R was combined with immunogold labeling of GluR1. Immunogold quantification was performed in two distinct Acb subregions, the shell, an area involved in processing incentive salience related to rewarding stimuli, and the core, an area involved in reward-seeking behaviors. We provide the first report that chronic morphine administration is associated with a receptor-phenotypic decrease in surface trafficking of GluR1 in Acb subregions. When compared to saline injected animals, morphine produced a decrease in plasma membrane GluR1 labeling in medium- and large-sized D1R expressing dendritic profiles in the Acb shell. In contrast, in the Acb core, surface GluR1 was decreased in small-sized dendrites that did not express the dopamine receptor. These results indicate that chronic intermittent injection of escalating doses of morphine is accompanied by ultrastructural plasticity of GluR1 in neurons that are responsive to glutamate and dopamine-induced D1R activation in the Acb shell, and neurons capable of responding to glutamate but not D1R receptor stimulation in the Acb core. Thus, AMPA receptor trafficking associated with chronic opiate exposure in functionally distinct areas of the Acb may be distinguished by D1R receptor activation, suggesting the potential for differing neural substrates of reward and motor aspects of addictive processes involving glutamate and dopamine signaling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18294632      PMCID: PMC2708174          DOI: 10.1016/j.expneurol.2008.01.012

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  54 in total

Review 1.  The synaptic framework for chemical signaling in nucleus accumbens.

Authors:  G E Meredith
Journal:  Ann N Y Acad Sci       Date:  1999-06-29       Impact factor: 5.691

2.  Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens.

Authors:  N Hirose; K Murakawa; K Takada; Y Oi; T Suzuki; H Nagase; A R Cools; N Koshikawa
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

Review 3.  How can drug addiction help us understand obesity?

Authors:  Nora D Volkow; Roy A Wise
Journal:  Nat Neurosci       Date:  2005-05       Impact factor: 24.884

Review 4.  The neural basis of addiction: a pathology of motivation and choice.

Authors:  Peter W Kalivas; Nora D Volkow
Journal:  Am J Psychiatry       Date:  2005-08       Impact factor: 18.112

5.  AMPA/kainate, NMDA, and dopamine D1 receptor function in the nucleus accumbens core: a context-limited role in the encoding and consolidation of instrumental memory.

Authors:  Pepe J Hernandez; Matthew E Andrzejewski; Kenneth Sadeghian; Jules B Panksepp; Ann E Kelley
Journal:  Learn Mem       Date:  2005 May-Jun       Impact factor: 2.460

6.  Expression of the transcription factor deltaFosB in the brain controls sensitivity to cocaine.

Authors:  M B Kelz; J Chen; W A Carlezon; K Whisler; L Gilden; A M Beckmann; C Steffen; Y J Zhang; L Marotti; D W Self; T Tkatch; G Baranauskas; D J Surmeier; R L Neve; R S Duman; M R Picciotto; E J Nestler
Journal:  Nature       Date:  1999-09-16       Impact factor: 49.962

7.  Nucleus accumbens long-term depression and the expression of behavioral sensitization.

Authors:  Karen Brebner; Tak Pan Wong; Lidong Liu; Yitao Liu; Paul Campsall; Sarah Gray; Lindsay Phelps; Anthony G Phillips; Yu Tian Wang
Journal:  Science       Date:  2005-11-25       Impact factor: 47.728

8.  Mechanisms of mu opioid receptor/G-protein desensitization in brain by chronic heroin administration.

Authors:  Catherine E Maher; Thomas J Martin; Steven R Childers
Journal:  Life Sci       Date:  2005-07-22       Impact factor: 5.037

9.  Overlapping intracellular and differential synaptic distributions of dopamine D1 and glutamate N-methyl-D-aspartate receptors in rat nucleus accumbens.

Authors:  Yuko Hara; Virginia M Pickel
Journal:  J Comp Neurol       Date:  2005-11-28       Impact factor: 3.215

10.  Increased AMPA GluR1 receptor subunit labeling on the plasma membrane of dendrites in the basolateral amygdala of rats self-administering morphine.

Authors:  Michael J Glass; Paul J Kruzich; Eric E O Colago; Mary Jeanne Kreek; Virginia M Pickel
Journal:  Synapse       Date:  2005-10       Impact factor: 2.562

View more
  27 in total

1.  Nucleus Accumbens AMPA Receptor Trafficking Upregulated by Food Restriction: An Unintended Target for Drugs of Abuse and Forbidden Foods.

Authors:  Kenneth D Carr
Journal:  Curr Opin Behav Sci       Date:  2016-06

2.  Narp deletion blocks extinction of morphine place preference conditioning.

Authors:  Hans S Crombag; Mercy Dickson; Megan Dinenna; Alexander W Johnson; Mark S Perin; Peter C Holland; Jay M Baraban; Irving M Reti
Journal:  Neuropsychopharmacology       Date:  2008-06-04       Impact factor: 7.853

Review 3.  Synaptic plasticity in the mesolimbic system: therapeutic implications for substance abuse.

Authors:  Billy T Chen; F Woodward Hopf; Antonello Bonci
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

4.  Calcium/calmodulin-dependent protein kinase II mediates hippocampal glutamatergic plasticity during benzodiazepine withdrawal.

Authors:  Guofu Shen; Bradley J Van Sickle; Elizabeth I Tietz
Journal:  Neuropsychopharmacology       Date:  2010-05-05       Impact factor: 7.853

5.  GluR2-3Y Inhibits the Acquisition and Reinstatement of Morphine-Induced Conditioned Place Preference in Rats.

Authors:  Xiao-Jing Lin; Jian-Jun Zhang; Long-Chuan Yu
Journal:  Neurosci Bull       Date:  2016-02-29       Impact factor: 5.203

Review 6.  The Opioid-Addicted Tetrapartite Synapse.

Authors:  Anna Kruyer; Vivian C Chioma; Peter W Kalivas
Journal:  Biol Psychiatry       Date:  2019-06-13       Impact factor: 13.382

Review 7.  Homeostatic regulation of reward via synaptic insertion of calcium-permeable AMPA receptors in nucleus accumbens.

Authors:  Kenneth D Carr
Journal:  Physiol Behav       Date:  2020-02-21

Review 8.  Plasticity of addiction: a mesolimbic dopamine short-circuit?

Authors:  Jason L Niehaus; Nelson D Cruz-Bermudez; Julie A Kauer
Journal:  Am J Addict       Date:  2009 Jul-Aug

9.  AMPA receptor subunit GluR1 downstream of D-1 dopamine receptor stimulation in nucleus accumbens shell mediates increased drug reward magnitude in food-restricted rats.

Authors:  K D Carr; L S Chau; S Cabeza de Vaca; K Gustafson; M Stouffer; D S Tukey; S Restituito; E B Ziff
Journal:  Neuroscience       Date:  2009-11-24       Impact factor: 3.590

10.  Sweetened-fat intake sensitizes gamma-aminobutyric acid-mediated feeding responses elicited from the nucleus accumbens shell.

Authors:  Sarah Newman; Lindsay Pascal; Ken Sadeghian; Brian A Baldo
Journal:  Biol Psychiatry       Date:  2013-01-08       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.